Steve Durant

Steve Durant is a seasoned professional in the field of oncology, currently serving as Vice President and Scientific Director at Evotec since January 2022. Previously, Steve held the position of Associate Principal Scientist at AstraZeneca from August 2010 to January 2022, where responsibilities included leading the development of key cancer therapeutics in the DNA Damage Response group. Prior roles included Team Leader at KuDOS Pharmaceuticals, and several postdoctoral research positions at esteemed institutions such as the University of Oxford, University of New Mexico, and Cancer Research UK. Steve obtained a PhD in Medical Oncology from the University of Glasgow, complemented by an MRes in Biological Sciences from The University of Manchester and a BSc in Applied and Human Biology from Aston University.